Zheng Wang
54Patents
7h-index
155Co-inventors
75Inventor score
Filing activity: Mar 14, 1994 → Jun 21, 2024
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6960449B2 | Class characterization of circulating cancer cells isolated from body fluids and methods of use | Physics | 156 | Expired |
| US5962237A | Method of enriching rare cells | Physics | 71 | Expired |
| US10253030B2 | Crystal form, preparation method and intermediate of dihydropyrido ring compound | Chemistry; Metallurgy | 24 | Active |
| US9156874B2 | Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs | Chemistry; Metallurgy | 17 | Active |
| US9095599B2 | O-(substituted benzyl) phosphoramidate compounds and therapeutic use | Chemistry; Metallurgy | 14 | Active |
| US8715715B2 | Dosage form for insertion into the mouth | Human Necessities | 12 | Active |
| US6316497A | Self-emulsifying systems containing anticancer medicament | Human Necessities | 10 | Expired |
| US8771736B2 | Dosage form for insertion into the mouth | Human Necessities | 7 | Active |
| US7668664B2 | Design and selection of genetic targets for sequence resolved organism detection and identification | Physics | 2 | Active |
| US9315755B2 | Catalytic system for preparation of high branched alkane from olefins | Chemistry; Metallurgy | 2 | Active |
| US10399981B2 | Crystal form A of 7-(cyclopropylmethyl)-1-(((cis )-4-hydroxy-4-methylcyclohexyl)methyl)-3-methyl-1H-purine-2,6-(3H,7H)-dione for treating liver diseases | Chemistry; Metallurgy | 1 | Active |
| US10428073B2 | Salt type and crystal type of 4H-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof | Emerging Cross-Sectional Technologies | 1 | Active |
| US8900634B2 | Diethylstilbestrol dosage form and methods of treatment using thereof | Human Necessities | 1 | Active |
| US10323046B2 | Method for preparing L-BPA | Emerging Cross-Sectional Technologies | 1 | Active |
| US9114073B2 | Dosage form for insertion into the mouth | Human Necessities | 1 | Active |
| US9114075B2 | Dosage form for insertion into the mouth | Human Necessities | 1 | Active |
| US9114074B2 | Dosage form for insertion into the mouth | Human Necessities | 1 | Active |
| US10874674B2 | Crystal form of orexin receptor antagonist compound, and preparation method and application thereof | Chemistry; Metallurgy | 0 | Active |
| US12116367B2 | Ring-modified proline short peptide compound and use thereof | Chemistry; Metallurgy | 0 | Active |
| US11255857B2 | Biomarkers for ovarian cancer CTAP3-related proteins | Physics | 0 | Active |
| US10479789B2 | Pyrido[1,2-A]pyrimidone analog, crystal form thereof, intermediate thereof and preparation method therefor | Chemistry; Metallurgy | 0 | Active |
| US9579295B2 | Dosage form for insertion into the mouth | Human Necessities | 0 | Active |
| US10941150B2 | Salt type and crystal type of 4h-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US10442811B2 | Crystal form A of 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-D] pyrimidin-4-amine, preparation process and use thereof | Chemistry; Metallurgy | 0 | Active |
| US10858322B2 | Process for preparing 1-isobutyryl-1′-((1-(4,4,4-trifluorobutyl)-4,5,6,7-tetrahydro-1H-benzo[D]imidazol-2-yl)methyl)spiro[azetidine-3,3′-indolin]-2′-one | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.